Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer by WEEKES, Colin D, VON HOFF, Daniel D, MA, Wen W, SHEEDY, Beth, IVERSON, Cory, MINER, Jeffrey N, ZANCONG SHEN, YEH, Li-Tain, DUBOWY, Ronald L, JEFFERS, Michael, RAJAGOPALAN, Prabhu, CLENDENINN, Neil J, ADJEI, Alex A, LEFFINGWELL, Diane P, ECKHARDT, S. Gail, GORE, Lia, LEWIS, Karl D, WEISS, Glen J, RAMANATHAN, Ramesh K, DY, Grace K

Get full text

A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer by Adjei, Alex A, Richards, Donald A, El-Khoueiry, Anthony, Braiteh, Fadi, Becerra, Carlos H R, Stephenson, Jr, Joe J, Hezel, Aram F, Sherman, Morris, Garbo, Lawrence, Leffingwell, Diane P, Iverson, Cory, Miner, Jeffrey N, Shen, Zancong, Yeh, Li-Tain, Gunawan, Sonny, Wilson, David M, Manhard, Kimberly J, Rajagopalan, Prabhu, Krissel, Heiko, Clendeninn, Neil J

Get full text

Abstract A88: Safety, pharmacokinetic, and pharmacodynamic results of BAY 86–9766, an oral MEK inhibitor, in combination with sorafenib, an oral multikinase inhibitor, in advanced... by Adjei, Alex A., Richards, Donald A., El-Khoueiry, Anthony, Becerra, Carlos H.R., Stephenson, Joe J., Leffingwell, Diane P., Iverson, Cory, Miner, Jeffrey N., Shen, Zancong, Gunawan, Sonny, Wilson, David, Manhard, Kimberly J., Dubowy, Ron L., Jeffers, Michael, Rajagopalan, Prabhu, Franklin, Wilbur A., Haney, Jerry, Lenhart, Patricia, Clendeninn, Neil J.

Get full text